Indivior shares price target cut, holds buy rating on financial projections

On Monday, Indivior PLC (NASDAQ: INDV) saw its stock price target reduced by Craig-Hallum from $24.00 to $20.00. Despite this change, the firm maintained its Buy rating on the pharmaceutical company's stock. The adjustment comes amid a reassessment of the company's financial projections, although the investment firm's overall outlook on Indivior remains positive.

Craig-Hallum's analysis suggests that the market for long-acting injectable (LAI) buprenorphine, a treatment for opioid dependence, is significantly underpenetrated, currently representing less than 7% of the overall oral buprenorphine market. The firm projects that this could increase to between 20% to 30% market penetration. Indivior's product, Sublocade, is expected to retain the majority of the market share due to its first-mover advantage and favorable pharmacokinetic (PK) profile.

Despite lowering the price target, Craig-Hallum believes that Indivior's shares are undervalued, trading at approximately four times forward adjusted operating profit. This valuation is seen even after adjusting the firm's financial expectations downward. The analyst expressed confidence in the potential for Indivior's stock value to increase as market estimates reach a lower bound.

The firm anticipates that the current period represents the peak of recent challenges faced by Indivior, with an expectation of improved fundamentals for Sublocade and the company's stock in the future. The sentiment suggests optimism for Indivior's performance going forward, despite the recent adjustments to financial forecasts.

In other recent news, Indivior has been the focus of several significant developments. The pharmaceutical company has maintained an Overweight rating from Piper Sandler, who underscored the firm's belief in the long-term growth potential of Sublocade, Indivior's product for treating opioid addiction. Despite a cautious outlook for 2024, the firm foresees double-digit annual growth for Sublocade, attributing this optimism to the product's patent protection and the expanding use of long-acting injectable therapies.

Indivior has also secured a major order from the Biomedical Advanced Research and Development Authority (BARDA) for OPVEE®, a medication designed to reverse opioid overdoses. This procurement, part of the U.S. government's strategy to enhance national readiness, is valued at $8.7 million and is set to bolster emergency response capabilities in the face of the ongoing opioid crisis.

However, the company has faced challenges with analysts from Craig-Hallum adjusting the price target for Indivior shares to $24, down from the previous $37, due to Medicaid-related issues and new market competition.

Despite these headwinds, the analyst reaffirmed belief in the company's resilience and potential growth, with Indivior's management expecting Sublocade to grow its net revenue by 25% year over year. These recent developments highlight the dynamic landscape for Indivior in the pharmaceutical industry.

InvestingPro Insights

With Indivior PLC (NASDAQ: INDV) in focus following Craig-Hallum's price target revision, current real-time data from InvestingPro provides additional context for investors. The company's market capitalization stands at approximately $1.22 billion, indicating its size within the pharmaceutical sector.

Despite recent challenges, an InvestingPro Tip highlights that management has been aggressively buying back shares, which can be a signal of confidence in the company's future prospects. Moreover, the company's gross profit margin remains robust at 79.42% for the last twelve months as of Q2 2024, underscoring the efficiency of its operations.

However, investors should be aware of some potential concerns. The company's price-to-earnings (P/E) ratio is currently negative at -9.1, reflecting earnings challenges in the recent period. Moreover, the stock has been trading near its 52-week low, with a price of $9.48 at the previous close, which may indicate market skepticism or a potential undervalued opportunity. The InvestingPro platform lists several more tips, including insights on shareholder yield and expectations for net income growth this year, which could be valuable for those considering an investment in Indivior.

For those interested in a deeper analysis, there are additional InvestingPro Tips available that could shed light on Indivior's financial health and stock performance. These include considerations of the company's cash burn rate, debt levels, and analyst earnings revisions, all of which are critical factors for making informed investment decisions. To explore these further, investors can visit InvestingPro at https://www.investing.com/pro/INDV.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.